二甲双胍抑制TGF-β诱导的人真皮成纤维细胞纤维化反应并减轻瘢痕疙瘩球体纤维化
研究在体外用TGF-β(10 ng/mL)刺激人真皮成纤维细胞并以二甲双胍(10 mM)处理,另在瘢痕疙瘩球体中以二甲双胍(100 mM)处理,评估细胞外基质(ECM)成分表达。结果显示二甲双胍可降低成纤维细胞及瘢痕疙瘩球体中胶原I/III等ECM成分表达,并减少p-Smad2/3复合蛋白,提示其可能作为瘢痕疙瘩治疗药物。
要点
- 二甲双胍(10 mM)降低TGF-β刺激的人真皮成纤维细胞中胶原I、III和弹性蛋白mRNA及胶原I蛋白水平。
- 二甲双胍(100 mM)降低瘢痕疙瘩球体中胶原I/III、纤连蛋白和弹性蛋白表达,并减少p-Smad2/3复合蛋白。
- 结果支持二甲双胍通过抑制TGF-β信号通路发挥抗纤维化作用,但仅为体外证据。
核心结论
- 二甲双胍可抑制TGF-β刺激的人真皮成纤维细胞及瘢痕疙瘩球体中的ECM成分表达,提示其有望用于瘢痕疙瘩治疗。
研究设计与样本
- 体外实验研究:以TGF-β(10 ng/mL)刺激人真皮成纤维细胞并予二甲双胍(10 mM)处理,另在瘢痕疙瘩球体中予二甲双胍(100 mM)处理,采用qPCR、western blot、免疫荧光和免疫组化评估ECM表达。
主要发现
- 人真皮成纤维细胞经二甲双胍(10 mM)处理后,胶原I型、III型和弹性蛋白mRNA水平显著下降,胶原I型蛋白水平显著下降。
- 瘢痕疙瘩球体经二甲双胍(100 mM)处理后,胶原I型、III型、纤连蛋白和弹性蛋白表达水平显著降低。
- 二甲双胍处理的瘢痕疙瘩球体中胶原I型、III型及p-Smad2/3复合蛋白减少。
关键数值与推荐
- 人真皮成纤维细胞刺激条件为TGF-β 10 ng/mL,二甲双胍处理浓度为10 mM;瘢痕疙瘩球体二甲双胍处理浓度为100 mM。
临床怎么用
- 结果提示二甲双胍可能作为抑制瘢痕疙瘩纤维化的候选药物,但当前仅为体外证据,尚不能直接指导临床用药剂量与方案。
局限性
- 研究为体外细胞与瘢痕疙瘩球体实验,未提供体内或临床数据,二甲双胍用于瘢痕疙瘩治疗的疗效与安全性尚需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Accumulation of excessive extracellular matrix (ECM) and aberrant transforming growth factor β (TGF-β) signaling pathway function can be potential therapeutic targets for keloid treatment. In this study, we examined the antifibrotic effect of metformin as a suppressor of TGF-β signaling pathways in human dermal fibroblasts (HDFs) and keloid spheroids. Human dermal fibroblasts were stimulated with TGF-β (10 ng/mL) and treated with metformin (10 mM). The mRNA and protein expression of ECM components were evaluated by quantitative polymerase chain reaction, western blot, and immunofluorescence assay. In addition, we immunohistochemically examined the expression levels of ECM proteins in keloid spheroids. After addition of metformin (10 mM), collagen types I and III and elastin mRNA levels were significantly decreased in HDFs, and collagen type I protein level was significantly decreased. In addition, the expression levels of collagen types I and III, fibronectin, and elastin were significantly reduced in keloid spheroids after treatment with metformin (100 mM). Collagen types I and III and p-Smad2/3 complex proteins were decreased in metformin-treated keloid spheroids. These findings indicated that metformin inhibits the expression of ECM components in TGF-β-stimulated HDFs and keloid spheroids. Therefore, we suggest the potential of metformin as an effective agent for the treatment of keloids.
引用
- Jeon HB, Roh H, Ahn HM, et al. Metformin Inhibits Transforming Growth Factor β-Induced Fibrogenic Response of Human Dermal Fibroblasts and Suppresses Fibrosis in Keloid Spheroids. Ann Plast Surg. 2021. PMID: 33141769. doi:10.1097/SAP.0000000000002574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。